FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of IL15/IL15Rα heterodimeric Fc-fused protein; it can be used in medicine. The resulting heterodimeric protein containing IL-15 attached by means of the first domain linker to an Fc-domain and a fragment of IL-15 receptor alpha (IL15Rα), attached to N-end of the second Fc-domain by means of the second domain linker, can be used for activation of T-cells and effective therapy of cancer.
EFFECT: obtaining Fc-fused proteins for the treatment of cancer.
19 cl, 106 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| ANTI-ApoC3 ANTIBODIES AND METHODS FOR THEIR USE | 2018 |
|
RU2781074C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
